Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Teaching Neuroanatomy Through a Historical Context.

Neuwirth LS, Dacius TF Jr, Mukherji BR.

J Undergrad Neurosci Educ. 2018 Jun 15;16(2):E26-E31. eCollection 2018 Spring. No abstract available.

2.

A Culturally Tailored Community Health Worker Intervention Leads to Improvement in Patient-Centered Outcomes for Immigrant Patients With Type 2 Diabetes.

Islam NS, Wyatt LC, Taher MD, Riley L, Tandon SD, Tanner M, Mukherji BR, Trinh-Shevrin C.

Clin Diabetes. 2018 Apr;36(2):100-111. doi: 10.2337/cd17-0068.

3.

Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.

Hegde UP, Mukherji B.

Cancer Immunol Immunother. 2017 Sep;66(9):1113-1121. doi: 10.1007/s00262-017-2007-x. Epub 2017 May 11. Review.

4.

Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.

Chhabra A, Mukherji B, Batra D.

Expert Opin Ther Targets. 2017 Feb;21(2):117-129. doi: 10.1080/14728222.2017.1270941. Epub 2016 Dec 20.

PMID:
27935327
5.

Medical Education: The Hot Seat.

Pal R, Kumar R, Pal S, Vidyasagar, Mukherji B, Debabrata S.

J Family Med Prim Care. 2016 Jan-Mar;5(1):20-3. doi: 10.4103/2249-4863.184618.

6.

Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells.

Chhabra A, Mukherji B.

Hum Immunol. 2016 Oct;77(10):905-911. doi: 10.1016/j.humimm.2016.06.011. Epub 2016 Jun 16.

PMID:
27320826
7.

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Hegde UP, Mukherji B, Grant-Kels JM.

Melanoma Manag. 2016 Mar;3(1):9-12. doi: 10.2217/mmt.15.39. Epub 2016 Feb 17. No abstract available.

8.

Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+)  CD25(-) and CD8(+) T cells attenuates effector function.

Jha SS, Chakraborty NG, Singh P, Mukherji B, Dorsky DI.

Immunology. 2015 May;145(1):124-35. doi: 10.1111/imm.12431.

9.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

10.

Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.

Chhabra A, Mukherji B.

J Immunol. 2013 Sep 15;191(6):3471-7. doi: 10.4049/jimmunol.1202350. Epub 2013 Aug 9.

11.

Evaluation of a community health worker pilot intervention to improve diabetes management in Bangladeshi immigrants with type 2 diabetes in New York City.

Islam NS, Wyatt LC, Patel SD, Shapiro E, Tandon SD, Mukherji BR, Tanner M, Rey MJ, Trinh-Shevrin C.

Diabetes Educ. 2013 Jul-Aug;39(4):478-93. doi: 10.1177/0145721713491438. Epub 2013 Jun 7.

12.

Immunology of melanoma.

Mukherji B.

Clin Dermatol. 2013 Mar-Apr;31(2):156-65. doi: 10.1016/j.clindermatol.2012.08.017.

PMID:
23438379
13.

Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

Chakraborty NG, Yadav M, Dadras SS, Singh P, Chhabra A, Feinn R, Kerr PE, Grant-Kels JM, Mukherji B, Hegde UP.

Hum Immunol. 2013 May;74(5):640-7. doi: 10.1016/j.humimm.2013.01.015. Epub 2013 Feb 4.

PMID:
23391568
14.

T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Kaur N, Naga OS, Norell H, Al-Khami AA, Scheffel MJ, Chakraborty NG, Voelkel-Johnson C, Mukherji B, Mehrotra S.

Cytokine. 2011 Aug;55(2):307-17. doi: 10.1016/j.cyto.2011.04.014. Epub 2011 May 23.

15.

Metastatic melanoma in the older patient: immunologic insights and treatment outcomes.

Hegde UP, Chakraborty N, Mukherji B, Grant Kels JM.

Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):185-93. doi: 10.1586/erp.11.14. Review.

PMID:
21476820
16.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B; UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.

Clin Immunol. 2010 Sep;136(3):338-47. doi: 10.1016/j.clim.2010.04.013. Epub 2010 May 23.

17.

The oxazolidinone derivative locostatin induces cytokine appeasement.

Ménoret A, McAleer JP, Ngoi SM, Ray S, Eddy NA, Fenteany G, Lee SJ, Rossi RJ, Mukherji B, Allen DL, Chakraborty NG, Vella AT.

J Immunol. 2009 Dec 1;183(11):7489-96. doi: 10.4049/jimmunol.0901414. Epub 2009 Nov 16.

18.

Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma.

Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B.

Clin Dermatol. 2009 Nov-Dec;27(6):603-13. doi: 10.1016/j.clindermatol.2008.09.019. Review.

PMID:
19880048
19.

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S.

Cancer Res. 2009 Aug 1;69(15):6282-9. doi: 10.1158/0008-5472.CAN-09-1176. Epub 2009 Jul 28.

20.

Production of a new antibacterial antibiotic from a mutated strain of Streptomyces kanamyceticus M27 in submerged fermentation.

Mukherji B, Chattopadhyay P, Ray L.

Hindustan Antibiot Bull. 2005 Feb-2006 Nov;47-48(1-4):1-6.

PMID:
18697724
21.

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B.

J Immunol. 2008 Jul 15;181(2):1063-70.

22.

Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Chhabra A, Chakraborty NG, Mukherji B.

Clin Immunol. 2008 Mar;126(3):251-9. doi: 10.1016/j.clim.2007.11.011. Epub 2008 Jan 14.

23.

Macrophages as stimulators of MART-1 27-35 epitope-specific human cytolytic T lymphocytes in vitro.

Mehrotra S, Zaidi N, Chakraborty NG, Mukherji B.

Pathobiology. 2006;73(5):238-43.

PMID:
17314494
24.

Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor.

Chhabra A, Mehrotra S, Chakraborty NG, Dorsky DI, Mukherji B.

Eur J Immunol. 2006 Dec;36(12):3167-74.

25.

Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death.

Mehrotra S, Chhabra A, Hegde U, Chakraborty NG, Mukherji B.

J Leukoc Biol. 2007 Feb;81(2):539-47. Epub 2006 Oct 24.

PMID:
17062604
26.

Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro.

Chattopadhyay S, Mehrotra S, Chhabra A, Hegde U, Mukherji B, Chakraborty NG.

J Immunol. 2006 Jan 15;176(2):984-90.

27.

Regulatory T cells and tumor immunity.

Chattopadhyay S, Chakraborty NG, Mukherji B.

Cancer Immunol Immunother. 2005 Dec;54(12):1153-61. Epub 2005 May 3. Review.

PMID:
15868167
28.

Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.

Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG.

Immunology. 2004 Dec;113(4):472-81.

29.

Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.

Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B.

J Immunol. 2004 Nov 15;173(10):6017-24.

30.

Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.

Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DI.

Eur J Immunol. 2004 Oct;34(10):2824-33.

31.

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.

Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B.

Hum Immunol. 2004 Aug;65(8):794-802.

PMID:
15336780
32.

Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses.

Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH.

J Immunother. 2004 May-Jun;27(3):191-200.

PMID:
15076136
33.

High Altitude induced Ortner's Syndrome.

Panwar SS, Mehta AK, Verma RK, Mukherji B.

Med J Armed Forces India. 2004 Apr;60(2):182-3. doi: 10.1016/S0377-1237(04)80116-3. Epub 2011 Jul 21. No abstract available.

34.

Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.

Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B.

Cancer Res. 2003 Sep 1;63(17):5607-14.

35.

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS.

Clin Cancer Res. 2003 Mar;9(3):998-1008.

36.

Stimulatory and inhibitory maturation of human macrophage-derived dendritic cells.

Chakraborty A, Li L, Chakraborty NG, Mukherji B.

Pathobiology. 1999;67(5-6):282-6.

PMID:
10725803
37.

Increased intraocular pressure and visual field defects in high resistance wind instrument players.

Schuman JS, Massicotte EC, Connolly S, Hertzmark E, Mukherji B, Kunen MZ.

Ophthalmology. 2000 Jan;107(1):127-33.

PMID:
10647731
38.

Stimulatory and inhibitory differentiation of human myeloid dendritic cells.

Chakraborty A, Li L, Chakraborty NG, Mukherji B.

Clin Immunol. 2000 Feb;94(2):88-98.

PMID:
10637093
39.

Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome.

Chakraborty N, Bilgrami S, Maness L, Guo C, Perez-Diez A, Mukherji B, Tutschka P.

Bone Marrow Transplant. 1999 Oct;24(8):837-43.

40.
41.

Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.

Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL, Dorsky D, Clive J, Mukherji B, Tutschka PJ.

Bone Marrow Transplant. 1999 Mar;23(5):469-74.

42.

Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

Pérez-Díez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B.

Cancer Res. 1998 Dec 1;58(23):5305-9.

43.

Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS.

J Immunol. 1998 Nov 15;161(10):5607-13.

44.

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma.

Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT, Mukherji B.

Cancer Immunol Immunother. 1998 Sep;47(1):58-64.

PMID:
9755879
45.

Human melanoma-specific, noncytolytic CD8+ T cells that can synthesize type I cytokine.

Chakraborty NG, Mukherji B.

Cancer Res. 1998 Apr 1;58(7):1363-6.

46.
47.

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, et al.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82.

48.

Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients.

Yamasaki S, Okino T, Chakraborty NG, Adkisson WO, Sampieri A, Padula SJ, Mauri F, Mukherji B.

Cancer Immunol Immunother. 1995 Apr;40(4):268-71.

PMID:
7750125
49.

Immunobiology and immunotherapy of melanoma.

Mukherji B, Chakraborty NG.

Curr Opin Oncol. 1995 Mar;7(2):175-84. Review.

PMID:
7756383
50.

Demonstration of differences in vascular permeability in experimental tumors by use of 19F magnetic resonance imaging.

Meyer KL, Joseph PM, Mukherji B, LiVolsi VA, Lin R, Phelan-Belfield M, Salscheider M.

Acad Radiol. 1994 Oct;1(2):106-13.

PMID:
9419473

Supplemental Content

Loading ...
Support Center